Amarin remains undervalued under almost any scenario, says Cowen » 07:5101/2201/22/21
Cowen analyst Ken…
Cowen analyst Ken Cacciatore believes Amarin shares remain undervalued remain undervalued under almost any scenario and said its valuation appears too discounted. He believes the company's best path forward it to cease US promotional spending to maximize profitability and then sell the company for European value, Cacciatore maintained his Outperform rating and $10 price target on Amarin shares.
Fly Intel: After-Hours Movers » 18:3501/2101/21/21
SIVB, WAL, INDB, OZK, FLDM, MNOV, SWIR, ALDX, AMRN, IBM, STX, PPG, ISRG, CSX, PGEN, ACB, F
Check out this evening's…
Amarin announces CSC included icosapent ethyl in CD prevention guidelines » 18:2701/2101/21/21
The company states:…
The company states: "Amarin announced that the Chinese Society of Cardiology, or CSC, has included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as published in the Chinese Journal of Cardiovascular Diseases. The guideline authors include "icosapent ethyl grams twice a day as a treatment consideration to further lower atherosclerotic cardiovascular disease (ASCVD) in the appropriate patient population. In November 2020, Amarin shared positive, statistically significant top-line results from a Phase 3 clinical trial of VASCEPA conducted in China by Amarin's partner, Edding. The study, which investigated VASCEPA as a treatment for patients with very high triglycerides (greater than or equal to500 mg/dL), met its primary efficacy endpoint and demonstrated a safety profile similar to placebo. This pivotal study mirrored Amarin's MARINE study in patients from the United States and other countries and showed consistency across the Chinese and non-Chinese study populations. These findings will provide support as Edding progresses towards and through the next steps of regulatory submission and review of VASCEPA for potential approval in Mainland China. The CSC recommendation is classified as a Category IIa recommendation denoting that icosapent ethyl is useful and effective and should be considered for treatment of at-risk patients. The classification is an Evidence Level B recommendation which reflects that the evidence comes from a single randomized trial or multiple large non-randomized studies. CSC cited that its recommendations are supported by the results of the REDUCE-IT cardiovascular outcomes study. The CSC does not provide endorsements of any brand name commercial product. Accordingly, CSC Guidelines for Primary Prevention of Cardiovascular Diseases reference icosapent ethyl. The CSC guideline does not reference VASCEPA, the brand name of icosapent ethyl in the United States, and such guideline should not be construed as an endorsement or approval by the CSC of VASCEPA."
FuboTV jumps as Barrington says buy, Einhorn highlights gains » 13:4801/2101/21/21
FUBO, REZI, DNMR, NCR, CHNG
Shares of FuboTV (FUBO)…
Align Technology establishes global corporate headquarters in Tempe » 08:3201/2001/20/21
Align Technology announced that it established its new global corporate headquarters in Tempe, Arizona, effective January 1. The company's San Jose campus remains the hub for its global innovation, product, and marketing organization and will become home to its new Digital Innovation Center, currently under construction. As part of the new corporate headquarters move, Align Technology President and CEO Joe Hogan, CFO and Senior Vice President, Global Finance John Morici, Senior Vice President, Chief Legal and Regulatory Officer Julie Coletti, and Senior Vice President, Global HR Stuart Hockridge have relocated their offices to Tempe. Approximately 150 employees, mostly in corporate general and administrative roles, have been offered relocation packages. These employees have the option to relocate to Tempe or to continue working from their current locations. Relocation is not required and there are no layoffs associated with this move.
Progenity reaches 2M test milestone » 07:3101/2001/20/21
Progenity has reported…
Progenity has reported the completion of two million diagnostic tests by its CLIA-certified and CAP-accredited laboratory in Ann Arbor, Michigan. This notable milestone comes as Progenity celebrates the ten-year anniversary of the company's founding.
Fulcrum Therapeutics 4M share Spot Secondary priced at $11.00 » 06:0701/2001/20/21
SVB Leerink, Piper…
SVB Leerink, Piper Sandler and Credit Suisse acted as joint book running managers for the offering.
ShockWave Medical downgraded to Neutral from Overweight at Piper Sandler » 05:0001/2001/20/21
Piper Sandler analyst…
Piper Sandler analyst Adam Maeder downgraded ShockWave Medical to Neutral from Overweight with a price target of $132, up from $96. The analyst steps to the sidelines "for the time being due to valuation." Additionally, he believes the resurgence of COVID-19 cases and "fairly high" buy-side expectations make for a "less-than-optimal" setup heading into the Q4 results. Maeder thinks the stock already reflects some upside to numbers and is unsure how much more multiple expansion will materialize over the next 12 months.
Omnicell price target raised to $140 from $125 at Benchmark » 04:5701/2001/20/21
Benchmark analyst Bill…
Benchmark analyst Bill Sutherland raised the firm's price target on Omnicell to $140 from $125 and keeps a Buy rating on the shares after the company last week issued a preliminary Q4 beat, increased 2021 guidance and established 2025 growth targets that include five-year annual growth of 50% for its software-as-a-service and technology enabled service offerings. The strong outlook reflects the increased stress on hospital pharmacy management during the pandemic and a greater recognition of Omnicell's automated pharmacy benefits, Sutherland tells investors in a research note.
Inspire appoints Bryan Phillips as chief compliance officer, general counsel » 16:0801/1901/19/21
Inspire Medical (INSP)…
Inspire Medical (INSP) announced the appointment of Bryan Phillips as senior VP, general counsel, chief compliance officer and corporate secretary. Phillips is a legal executive with broad corporate experience in the healthcare industry.Most recently, Phillips served as chief legal officer at Cerevel Therapeutics (CERE).